Compare

GT Biopharma, Inc. vs Revium Rx. vs Dermata Therapeutics, Inc. vs Processa Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	GT Biopharma, Inc. GTBP	Revium Rx. RVRC	Dermata Therapeutics, Inc. DRMA	Processa Pharmaceuticals, Inc. PCSA
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	-$28.35M	-$13.45M	-$7.56M	-$13.56M
EPS (Diluted)	-$6.68	-$0.22	-$8.16	-$10.36
Operating cash flow	-$12.91M	n/a	-$7.76M	-$11.39M
Free cash flow	n/a	n/a	n/a	n/a
Cash & equivalents	$6.81M	$1.68M	$7.52M	$5.54M
Total assets	$8.11M	$8.30M	$7.86M	$7.81M
Total liabilities	n/a	$1.42M	$1.64M	$2.24M
Shareholders' equity	$5.79M	$6.88M	$6.22M	$5.58M
Return on year-end equity	-490.0%	-195.5%	-121.5%	-243.2%
Shares outstanding	25.53M	60.73M	2.66M	2.57M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	GT Biopharma, Inc.	Revium Rx.	Dermata Therapeutics, Inc.	Processa Pharmaceuticals, Inc.
Latest	$0 Ended 2020-12-31	n/a	n/a	$0 Ended 2022-12-31
1 year earlier	$0 Ended 2019-12-31	n/a	n/a	$0 Ended 2021-12-31
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a